| Document |
Document Title |
|
JP7241025B2 |
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...
|
|
JP2023034088A |
To provide a fluorine-containing cyclic sulfonyl imide salt having excellent handleability as powder.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same or different to...
|
|
JP2023034110A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high heat resistance and low metal corrosiveness.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same ...
|
|
JP2023034081A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high heat resistance and low metal corrosiveness.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same ...
|
|
JP2023034097A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high heat resistance and low metal corrosiveness.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same ...
|
|
JP2023034103A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high solution stability.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same or different to represent...
|
|
JP2023034118A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high heat resistance and low metal corrosiveness.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same ...
|
|
JP2023034119A |
To provide a fluorine-containing cyclic sulfonyl imide salt having high heat resistance.A fluorine-containing cyclic sulfonyl imide salt is represented by the general formula (1) {where each R may be the same or different to represent a ...
|
|
JP2023508930A |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using them. [Selection figure] None
|
|
JP2023508909A |
4-phenyl-N-(phenyl) as arylhydrocarbon receptor (AHR) agonists for the treatment of angiogenesis-related disorders or inflammatory diseases such as retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer Thiazol-2-amine and 4-(p...
|
|
JP2023508142A |
The present invention relates to compounds of formula (I) and their use in the treatment or prevention of inflammatory diseases or diseases associated with an undesired immune response, wherein RA1, RA2, RC., and RD.is as defined herein.
|
|
JP2023507774A |
As used herein, for inhibiting protein tyrosine phosphatases, such as non-receptor type 2 protein tyrosine phosphatase (PTPN2) and/or non-receptor type 1 protein tyrosine phosphatase (PTPN1) and treatment with PTPN1 or PTPN2 inhibitors P...
|
|
JP2023507571A |
The present invention relates to compounds that inhibit Son of Sevenless Homolog 1 (SOS1) activity. In particular, the invention relates to compounds, pharmaceutical compositions, and methods of use, eg, methods of treating cancer using ...
|
|
JP7227916B2 |
The present invention refers to compounds, and to pharmaceutical compositions containing said compounds, of the following formula (I) or a pharmaceutically acceptable salt thereof: including any stereochemically isomeric form thereof, wh...
|
|
JP2023504645A |
The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bile acid tra...
|
|
JP2023504644A |
The present invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bile acid transport (LBAT) inhibitory...
|
|
JP2023504643A |
The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bi...
|
|
JP7217762B2 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
JP7204005B2 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
JP2022554392A |
The present disclosure is directed to the use of MrgprX2 antagonists in the treatment of inflammatory disorders, eg, inflammatory disorders of the skin. The present invention is also directed to pharmaceutical compositions for topical or...
|
|
JP2022553268A |
Alkali metal salts of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazo
l-5-yl]benzamide and formulations thereof are provided. The salts find particular utility in treating or preventing disorders or conditions that are ameli...
|
|
JP2022552496A |
Compounds, compositions and methods for treating diseases, disorders or conditions affected by modulation of DHODH are disclosed. Such compounds have the following formula I [wherein R1, R2, R3, and Q are defined herein]. [Chemical 1]
|
|
JP7189369B2 |
The present disclosure provides a compound of Formula (I):or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...
|
|
JP7182553B2 |
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and composition...
|
|
JP2022548312A |
The present application relates to lipids of formula (A-1) and compositions therewith. Lipid nanoparticles (eg, empty LNPs or loaded LNPs) include such lipids as well as additional lipids such as phospholipids, structured lipids, PEG lip...
|
|
JP2022547617A |
Kind Code: A1 The present disclosure provides compounds and pharmaceutical compositions for the modulation of IL-17A that are useful in treating inflammatory diseases such as psoriasis. [Selection figure] None
|
|
JP7149271B2 |
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...
|
|
JP2022140725A |
To provide methods for treating disease.The present disclosure provides a compound of a Formula (I) in the figure or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical comp...
|
|
JP2022541780A |
Scaffold compounds are used to design small molecule compounds to identify inhibitors of inflammation through structure-activity relationship studies. Methods include the use of small molecule compounds to inhibit, prevent and treat infl...
|
|
JP7120549B2 |
Disclosed is a compound of formula (I):wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and metho...
|
|
JP2022536419A |
These compounds are glutamine transporter inhibitors, eg, alanine, serine, cysteine preferred transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful for treating a variety of diseases, disorders, or conditions, inc...
|
|
JP2022535672A |
A compound of formula 1 [Chemical 1] or tautomers thereof, and pharmaceutically acceptable salts of this compound or tautomers (wherein L, R1, R2, R3, R4and R5is defined herein) is disclosed. This disclosure also relates to materials and...
|
|
JP2022110130A |
To provide compounds and pharmaceutical compositions for use as pharmaceuticals.The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein A is benzimidazo...
|
|
JP7101728B2 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
JP2022530623A |
The present disclosure relates to compounds of formulas (I)-(VI) useful as modulators of USP36. The compound is further useful in the treatment of USP36 inhibition and diseases or disorders associated with USP36 inhibition. For example, ...
|
|
JP2022528950A |
The present invention relates to a novel compound having anticancer activity and a method for producing the same, and more particularly to a novel compound which suppresses the expression of AIMP2-DX2 and exhibits excellent anticancer ac...
|
|
JP2022527294A |
The present disclosure relates to therapeutic methods or agents in inflammatory diseases and specific neuropathy associated with inflammatory signaling processes including, but not limited to, compounds, pharmaceutical compositions conta...
|
|
JP2022082139A |
To provide a method for readily producing vinylbisfluoroalkane sulfonylimide.A method for producing vinylbisfluoroalkane sulfonylimide includes reacting an alkyne compound represented by formula (I) with bisfluoroalkane sulfonylimide rep...
|
|
JP2022526450A |
Disclosed herein are compounds that regulate the interaction of CD-40-CD40L, including pharmaceutically acceptable salts, esters, prodrugs, hydrates and mutants thereof. be. These compounds are useful in treating, ameliorating, or preven...
|
|
JP7073269B2 |
The present invention refers to compounds of formula I or II endowed with DDX3 inhibitory activity, relative pharmaceutical compositions and their use as antihyperproliferative agents. (I) or (II)
|
|
JP7072569B2 |
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)
|
|
JP2022520698A |
The present invention relates to compound (I) :. [Chemical 1] Regarding the method of synthesizing1Represents methyl or methyl-d3 and thus corresponds to 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or its methyl-d3 deuterated form. These...
|
|
JP2022519370A |
The present invention relates to a 1,2,5-benzothiadiazepine derivative of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporters (ASBT) and / or liver bile acid transport (LBAT) inhibito...
|
|
JP7021104B2 |
The present invention relates to heteroaromatic compounds which have two different reactive groups, their use in the synthesis of asymmetrically substituted compounds, and synthesis processes in which the compounds according to the inven...
|
|
JP2022507879A |
In the present invention, the formula (Ia) (in the formula, the XY group is -NHSO2-Or-SO2NH-is; R1Is H or alkyl; R2Is selected from COOH and tetrazolyl groups; R3Is selected from H, Cl and alkyl; R4Is selected from H, Cl and F; R5H, alky...
|
|
JP2022507020A |
A pharmaceutical composition comprising a compound useful for treating cancer and the above-mentioned compound is provided herein. Certain cancers include those mediated by YAP / TAZ or regulated by the interaction between YAP / TAZ and ...
|
|
JP2022007984A |
To provide a novel agricultural chemical, in particular a herbicide.The present invention discloses a ketone or oxime compound represented by formula (1): [where B is B-1, B-2 or B-3, Q is an oxygen atom, NOR7 or the like, R6 is a hydrog...
|
|
JP2021536458A |
The present invention relates to aryl hydrocarbon receptor antagonists, as well as methods of regulating aryl hydrocarbon receptor activity, and methods of growing hematopoietic stem cells by culturing hematopoietic stem cells or progeni...
|
|
JP6975860B2 |
A compound of formula (I):which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1, and MOF.
|
|
JP6963599B2 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
